Rigel posts $13.2M Q3 profit as breast cancer drug VEPPANU begins selling

Rigel Pharmaceuticals reported a third-quarter 2026 profit of $13.2 million on 5 November. Total revenue was $80.9 million, of which product sales accounted for $72.3 million. The release gives no breakdown of the remaining $8.6 million.

VEPPANU (vepdegestrant) supplied $6.6 million of the product total, roughly nine per cent. The drug reached US patients on 13 August, so the figure covers under two months of selling. It is approved for advanced breast cancer that is ER+/HER2- and carries an ESR1 mutation. It is billed as the first PROTAC to win FDA approval, which makes it the first commercial test of that drug design in the US.

Rigel now expects 2026 revenue of about $290 million to $295 million, an increase on its earlier outlook. The reported facts do not say what the prior range was, or how much of the new figure depends on VEPPANU compared with the company's existing products.

Separately, Rigel's partner Knight has secured approval from Colombia's regulator, INVIMA, for TAVALISSE in chronic immune thrombocytopenia (ITP). That widens the drug's reach in Latin America. No financial terms or launch timing were disclosed.